cladribine has been researched along with Hepatitis B Virus Infection in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cola, G; Di Mauro, G; Grimaldi, A; Landi, D; Marfia, GA; Mataluni, G; Nicoletti, CG | 1 |
| Annovazzi, P; Brescia Morra, V; Buonomo, AR; Buscarinu, MC; Calabrese, M; Cavalla, P; Cocco, E; Cordioli, C; De Angelis, M; De Luca, G; Di Filippo, M; Ferraro, D; Gajofatto, A; Gasperini, C; Gentile, I; Lanzillo, R; Maniscalco, GT; Moccia, M; Nociti, V; Paolicelli, D; Petruzzo, M; Pinardi, F; Radaelli, M; Scotto, R; Solaro, C; Spiezia, AL; Tomassini, V; Viceconte, G; Zappulo, E | 1 |
| Busuttil, DP; Chasty, RC; Copplestone, JA; Fraser, M; Prentice, AG | 1 |
3 other study(ies) available for cladribine and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus.
Topics: Cladribine; COVID-19; Hepatitis B; Hepatitis B virus; Humans; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Topics: Antiviral Agents; Cladribine; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Middle Aged; Multiple Sclerosis; Retrospective Studies; Rituximab; Virus Activation | 2022 |
Delayed reactivation of hepatitis B infection after cladribine.
Topics: Aged; Cladribine; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Recurrence | 1996 |